Semaglutide, known as Ozempic or Wegovy, initially for type 2 diabetes, shows potential in weight loss, heart failure, and chronic kidney disease. A recent study in the New England Journal of Medicine suggests it improves knee pain in obese individuals with osteoarthritis, with participants losing 13% body weight on average and reporting significant pain reduction.